Steroids for acute spinal cord injury

Area of Science:

• Neurology
• Traumatology
• Pharmacology

Background:

• Acute spinal cord injury (SCI) is a severe condition predominantly affecting young males.
• Early steroid administration aims to mitigate permanent paralysis.

Purpose of the Study:

• To review randomized controlled trials (RCTs) of steroid treatment for acute SCI.

Main Methods:

• Comprehensive literature search including Cochrane Injuries Group strategy, National Acute Spinal Cord Injury Study (NASCIS) data, and Medline.
• Inclusion of all published/unpublished RCTs in any language.
• Data abstraction from original reports and direct author contact for additional data.

Main Results:

• Methylprednisolone sodium succinate is the primary steroid studied, showing improved neurologic outcomes up to one year post-injury.
• Efficacy demonstrated when administered within eight hours of injury with a specific dosage regimen (30mg/kg bolus, 5.4mg/kg/hr for 23 hours).
• Meta-analysis of key trials confirms significant motor function recovery with methylprednisolone initiated within eight hours.
• Extended treatment (48 hours total) shows additional benefits, particularly if initiated between three to eight hours post-injury.
• Methylprednisolone also shows efficacy in whiplash injuries and post-surgical recovery for lumbar disc disease.

Conclusions:

• High-dose methylprednisolone is the only pharmacotherapy with proven efficacy in Phase III RCTs for acute SCI when administered within eight hours.
• Extending methylprednisolone maintenance dose to 48 hours offers additional benefits if treatment initiation is delayed (3-8 hours post-injury).
• There is a critical need for further RCTs on pharmacological therapies for acute SCI.